GLP-1 Safety in Pregnancy: Evidence-Based Family Planning Guide

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Current clinical evidence suggests GLP-1 receptor agonists like Ozempic should be discontinued before pregnancy, though animal studies show mixed results and human data remain limited. The FDA has not established definitive safety profiles for these medications during human pregnancy, making provider consultation essential before conception or if pregnancy occurs.

If you're considering GLP-1 therapy while planning family expansion, understanding your individual metabolic and genetic predispositions can help frame a more informed conversation with your healthcare provider. PlexusDx supports precision wellness by offering genetic insights that may help contextualize treatment timing and family planning decisions.

What Current Evidence Shows About GLP-1s and Pregnancy Risk

Animal reproduction studies with semaglutide and tirzepatide showed fetal harm at doses above therapeutic ranges, though no adequate human studies exist to confirm risk at clinical doses. The FDA classifies these medications in Pregnancy Category C, meaning risk cannot be ruled out but human data is insufficient.

A 2023 review in Diabetes Care noted that pregnancy registries for GLP-1 users remain sparse, and most clinical guidance recommends stopping these medications three months before attempting conception. Healthcare providers emphasize that maternal glycemic control is critical during pregnancy, making individualized planning necessary rather than blanket recommendations.

Timeline and Safety Considerations Across Pregnancy Stages

The periconception period—three months before through the first trimester—represents the highest-risk window for medication effects on fetal development. Below is a framework healthcare providers use when counseling patients on GLP-1 use and family planning timelines.

Pregnancy Stage	Clinical Consideration
Pre-conception (3+ months before)	Discontinue GLP-1; optimize glycemic control with alternative agents; genetic testing may reveal metabolic predispositions.
First trimester (weeks 1-12)	Critical organ development; GLP-1 RAs contraindicated; insulin or other agents preferred for glucose management.
Second and third trimester	Organ systems established; GLP-1 data still insufficient; providers typically continue alternative agents for safety.
Postpartum and breastfeeding	Limited data on GLP-1 excretion in breast milk; providers assess individual risk-benefit before resuming therapy.

Alternative Strategies for Metabolic Health During Family Planning

Patients requiring glucose management during pregnancy can transition to insulin, metformin, or other agents with stronger safety profiles. Many healthcare providers recommend preconception counseling to identify the most appropriate alternative based on individual metabolic profiles and diabetes type.

For those not yet pregnant but planning conception within one to three years, understanding your genetic predispositions in GLP-1 and metabolic pathways may help you and your provider design a timeline that addresses weight and glucose management before discontinuation. This approach supports both fertility goals and long-term health outcomes.

Who Should Have This Conversation With Their Provider Now

Any patient assigned female at birth or capable of pregnancy who is currently using or considering GLP-1 therapy should discuss family planning timelines with their healthcare provider before starting treatment. This includes those with type 2 diabetes, PCOS, or weight management goals who may be planning pregnancy within the next two to five years.

If you discover you are pregnant while taking a GLP-1 medication, do not abruptly stop treatment without guidance—contact your healthcare provider immediately to discuss safe discontinuation and transition to pregnancy-safe alternatives. Emergency discontinuation can sometimes carry greater risk than a planned taper and medication switch under medical supervision.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around your individual predispositions in GLP-1 receptor pathways and metabolic genes, potentially revealing why you respond to these medications and whether your metabolic profile suggests higher benefit from early intervention or different timing. This information should be interpreted with a qualified healthcare provider as part of your family planning discussion.

The test examines variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to GLP-1 therapies and metabolic regulation. Understanding these predispositions does not predict exact medication response or pregnancy outcome, but can help you and your provider frame a more personalized timeline for treatment, discontinuation, and family planning.

If you are considering GLP-1 therapy or are already using it and planning pregnancy, a genetic assessment can support a conversation with your provider about whether early intervention before conception is optimal for your situation, or whether alternative management strategies may better align with your family planning timeline.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.